A Phase II Study of PNT2258 in Patients With Richter's Transformation (RT)
A study for patients with Richter's Transformation (RT) using study drug PNT2258
Sponsor: Pronai Therapeutics
Enrolling: Male and Female Patients
IRB Number: AAAP4516
U.S. Govt. ID: NCT02378038
Contact: Nicole Lamanna: 646-317-5205 / nl2129@columbia.edu
Additional Study Information: This study is for patients with Richter's transformation (RT). The purpose of this study is to see if a new type of investigational drug called PNT2258 that may be effective in blocking the "on" signal to cancer cells, eventually causing them to die. We are trying to see if PNT2258 provides evidence of anti-tumor effect by measuring what happens to tumors after exposure to PNT2258.
This study is closed
Investigator
Nicole Lamanna, MD
Do You Qualify?
Do you have a confirmed diagnosis of Richter's transformation (RT) from chronic lymphocytic leukemia/small lymphocytic lymphoma? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Nicole Lamanna
nl2129@columbia.edu
646-317-5205